The use of APX3330 facilitates endeavors in further understanding of APE1/Ref-1 redox interactions and isolation, providing an opportunity for specific therapeutics targeting pathophysiological mechanisms of IBD. This evidence concerns the gene APEX1 and inflammatory bowel disease.